Stockscreener 앱 받기
5.08
2.63%
0.13
시간 외 거래:
4.98
-0.10
-1.97%
전일 마감가:
$4.95
열려 있는:
$4.88
하루 거래량:
14,220
Relative Volume:
1.53
시가총액:
$70.58M
수익:
$57.94M
순이익/손실:
$-2.34M
주가수익비율:
-30.49
EPS:
-0.1666
순현금흐름:
$3.82M
1주 성능:
-2.12%
1개월 성능:
-12.56%
6개월 성능:
-16.45%
1년 성능:
-25.73%
1일 변동 폭
$4.88
$5.13
1주일 범위
$4.88
$5.3892
52주 변동 폭
$4.88
$8.74
Champions Oncology Inc Stock (CSBR) Company Profile
명칭
Champions Oncology Inc
전화
410-369-0365
주소
855 N. WOLFE STREET, BALTIMORE, NJ
Compare CSBR vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CSBR
Champions Oncology Inc
|
5.08 | 68.77M | 57.94M | -2.34M | 3.82M | -0.1666 |
VRTX
Vertex Pharmaceuticals Inc
|
516.44 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.97 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
856.94 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
202.00 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
356.01 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Champions Oncology Inc Stock (CSBR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-12 | 업그레이드 | Craig Hallum | Hold → Buy |
| 2019-11-18 | 개시 | The Benchmark Company | Speculative Buy |
Champions Oncology Inc 주식(CSBR)의 최신 뉴스
NMAD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Champions Oncology Inc (CSBR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Champions Oncology (NASDAQ:CSBR) Stock Price Crosses Below 200 Day Moving AverageHere's Why - MarketBeat
Champions Oncology, Inc. Revenue Breakdown – NASDAQ:CSBR - TradingView
CSBR Stock Dips Post Q4 Earnings Despite Record Revenue Growth, AI Push - The Globe and Mail
Is Champions Oncology (NASDAQ:CSBR) In A Good Position To Invest In Growth? - Sahm
Champions Oncology Inc (CSBR) (Q4 2026) Earnings Call Highlights: Record Revenue and Positive ... By GuruFocus - Investing.com Canada
Champions Oncology Inc. (CSBR) Slides 8.75% as Selling Pressure IntensifiesVolume Spike Alerts - dars.gov.et
Champions Oncology Inc (CSBR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Champions Oncology Inc (CSBR) Institutional Confidence - TradingKey
Earnings call transcript: Champions Oncology posts record Q4 2026 revenue By Investing.com - Investing.com Nigeria
Champions Oncology Inc (CSBR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Champions Oncology Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Champions Oncology posts record Q4 2026 revenue - Investing.com
CSBR: Record revenue and positive Adjusted EBITDA achieved, with strong core services growth and margin gains - TradingView
CHAMPIONS ONCOLOGY, INC. FY 2026: Revenue $59.43M, EPS ($0.08) — 10-K Summary - TradingView
CSBR: Revenue up 4.4% to $59.4M, but net loss of $1.2M driven by higher R&D and operating costs - TradingView
Rising costs push Champions Oncology (NASDAQ: CSBR) into 2026 loss - Stock Titan
Champions Oncology, Inc. Reports Earnings Results for the Full Year Ended April 30, 2026 - marketscreener.com
Champions Oncology reports record $59.4M revenue, positive adjusted EBITDA for FY2026 - TradingView
CSBR: Record revenue and positive adjusted EBITDA achieved, driven by core research services growth - TradingView
CHAMPIONS ONCOLOGY ($CSBR) Releases Q4 2026 Earnings - Quiver Quantitative
Champions Oncology Q4 revenue rises; margin improves driven by cost discipline - TradingView
Champions Oncology Reports Record Annual Revenue of $59 Million - Eagle-Tribune
BRIEF-Champions Oncology Q4 Adjusted EPS USD 0.01 - TradingView
At fiscal year-end, Champions Oncology had $4.9M cash, no debt - Stock Titan
Champions Oncology Inc (CSBR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Champions Oncology Inc (CSBR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Champions Oncology Inc (CSBR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CSBR|Champions Oncology Inc|Price:6.160|Chg%:+0.030 - TradingKey
Champions Oncology, Inc. Revenue Breakdown – MUN:2I3 - TradingView
Enterprise value to EBITDA forward of Champions Oncology, Inc. – MUN:2I3 - TradingView
Champions Oncology, Inc. Revenue Breakdown – FWB:2I3 - TradingView
CSBR Q4'25 Earnings: EPS estimate is (0.05) USD - TradingView
CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside? - TradingView
2 Microcaps With Gross Margin Catalysts - Yahoo Finance
Zacks Initiates Coverage of Champions Oncology With Neutral Recommendation - Yahoo! Finance Canada
Champions Oncology (CSBR.US) will release its earnings report after market close on July 27. - Moomoo
Champions Oncology to announce Q4 and FY26 results on July 27 - scanx.trade
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Monday, July 27, 2026 - ACCESS Newswire
Champions Oncology Schedules Year-End Results Call for 4:30 p.m. - Stock Titan
Enterprise value to EBITDA forward of Champions Oncology, Inc. – SWB:2I3 - TradingView
Brain Tumor Treatment Market Size To Exceed $7.17 Billion By 2035 - SNS Insider
RadioMedix Appoints Brian A. Markison to Board of Directors - Yahoo Finance UK
Champions Oncology (CSBR) Declines Sharply, Approaches Key Support at $5.38Volatility Stop - dars.gov.et
RANI Stock Price and Chart — NASDAQ:RANI - TradingView
Enterprise value to EBITDA forward of Champions Oncology, Inc. – DUS:2I3 - TradingView
Enterprise value to EBIT forward of Champions Oncology, Inc. – DUS:2I3 - TradingView
Trading the Move, Not the Narrative: (CSBR) Edition - Stock Traders Daily
RXT Q1 2026 Earnings: EPS Misses Consensus by 69.49%, Shares SurgeProfit Recovery Report - dars.gov.et
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Champions Oncology Inc (CSBR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.03%
0.33%
자본화:
|
볼륨(24시간):